SiBionics and PharmaSens Explore Automated Insulin Delivery at EASD 2026
SiBionics presented new insights into automated diabetes care at EASD 2026, connecting continuous sensing with future treatment methods.
MILAN, Oct. 4, 2026 – SiBionics, a company exploring automated diabetes care, presented its "See More, Act Earlier" vision at the European Association for the Study of Diabetes (EASD) annual meeting in Milan. The approach integrates continuous glucose sensing with future diabetes treatment modalities.
The presentation was divided into three exhibition chapters. "See More: Beyond Glucose" focused on technologies enabling broader data collection and analysis, aiding in earlier detection of changes. Another segment examined how this deeper understanding can inform improved treatment decisions.
The "Act Earlier" chapter addressed the proactive utilization of collected data. The objective is to develop systems that not only measure glucose levels but also anticipate and prevent significant fluctuations, thereby reducing the treatment burden for individuals with diabetes and enhancing quality of life.
Collaboration with PharmaSens was mentioned as part of the development process. The companies aim to combine their technologies and expertise to create more seamless solutions for automated insulin delivery, a key goal in modern diabetes management.